Publications

Add filters (0)

69 results

Serological assessment of PRO-C16 (type XVI collagen formation) reflects intestinal fibrostenotic strictures in patients with crohn’s disease.

August 8, 2025

BMC Gastroenterol

Abstract BACKGROUND Fibrostenotic stricturing disease affects 30-50% of patients with Crohn’s disease (CD), leading to intestinal resection. Currently, there exists a great medical need to identify biomarkers related to fibrostenotic strictures for optimized patient management. Thus, we investigated PRO-C16 as a biomarker for intestinal fibrosis in patients with CD. METHODS Human serum from two independent […]

Read publication

Fibroblast activities are associated with prolonged QTc and pulmonary arterial hypertension in patients with systemic sclerosis.

August 1, 2025

Clin Exp Rheumatol

Abstract OBJECTIVES In systemic sclerosis patients (SSc), we aimed at exploring the potential of serum biomarkers of fibrosis and immune-cell activity to detect subclinical heart involvement determined by electrocardiographic (ECG) alterations. METHODS A panel of extracellular matrix (ECM) turnover biomarkers quantifying type III and VI collagen formation (PRO-C3 and PRO-C6), type IV collagen turnover (PRO-C4), […]

Read publication

Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.

July 1, 2025

J Hepatol

Abstract Fibrosis is a pathological condition characterised by excessive accumulation of extracellular matrix (ECM) components, particularly collagens, leading to tissue scarring and organ dysfunction. In fibrosis, an imbalance between collagen synthesis (fibrogenesis) and degradation (fibrolysis) results in the deposition of fibrillar collagens disrupting the structural integrity of the ECM and, consequently, tissue architecture. Fibrosis is […]

Read publication

Serum biomarkers of collagen remodeling are associated with intestinal fibrosis and differentiate stenotic from luminal Crohn’s disease patients: a pre- and post-resection longitudinal study.

June 4, 2025

J Crohns Colitis

Abstract BACKGROUND AND AIMS Crohn’s disease (CD) is characterized by progressive intestinal transmural damage, including fibrosis and strictures, which impair quality of life and require surgical intervention. No anti-stricture therapies are available, and no accurate biomarkers have been validated allowing prediction of strictures. Collagen fragments synthesis and remodeling show potential as markers of transmural disease […]

Read publication

Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients.

June 1, 2025

Proteomics

Abstract A common hallmark of chronic kidney disease (CKD) is kidney fibrosis, which manifests as an increased deposition and turnover of collagens in the kidneys. Current clinical methods of monitoring disease progression in CKD patients do not truly reflect alterations at the tissue level without the use of invasive biopsies. Naturally occurring urinary peptides associated […]

Read publication

Markers of Collagen Formation and Degradation in Serum and Pancreatic Fluid Collections in Patients With Acute and Chronic Pancreatitis.

February 1, 2025

Pancreas

Abstract OBJECTIVES Current knowledge on the fibro-inflammatory process underlying chronic pancreatitis originates from animal studies or human studies based on circulating biomarkers. To provide new insight into the underlying fibro-inflammatory processes, we simultaneously assessed fibrosis biomarkers in pancreatic fluid collections and the systemic circulation. MATERIALS AND METHODS This prospective observational cross-sectional study included patients with […]

Read publication

Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib.

January 7, 2025

Sci Rep

Abstract Understanding how inflammatory cytokines influence profibrogenic wound healing responses in fibroblasts is important for understanding the pathogenesis of fibrosis. TNF-α and IL-13 are key cytokines in Th1 and Th2 immune responses, respectively, while TGF-β1 is the principal pro-fibrotic mediator. We show that 12-day fibroblast culture with TNF-α or IL-13 induces fibrogenesis, marked by progressively […]

Read publication

Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy.

January 1, 2025

Front Endocrinol (Lausanne)

Abstract INTRODUCTION Decline in kidney function due to renal fibrosis is a potential side effect in patients with neuroendocrine neoplasm (NEN) undergoing Peptide Receptor Radionuclide Therapy (PRRT). We aimed to investigate the potential of circulating fibrosis markers reflecting formation and degradation of collagens in predicting decline in kidney function in NEN-patients undergoing PRRT. MATERIAL AND […]

Read publication

The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases.

September 1, 2024

Matrix Biol

Abstract Fibrosis, driven by fibroblast activities, is an important contributor to morbidity and mortality in most chronic diseases. Endotrophin, a signaling molecule derived from processing of type VI collagen by highly activated fibroblasts, is involved in fibrotic tissue remodeling. Circulating levels of endotrophin have been associated with an increased risk of mortality in multiple chronic […]

Read publication

The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death.

July 1, 2024

Diabetes Obes Metab

Abstract Fibrosis is a common feature of more than 50 different diseases and the cause of more than 35% of deaths worldwide, of which liver, kidney, skin, heart and, recently, lungs are receiving the most attention. Tissue changes, resulting in loss of organ function, are both a cause and consequence of disease and outcome. Fibrosis […]

Read publication